Highlights BeyondSpring Inc.

Equities

BYSI

KYG108301006

Delayed Nasdaq Other stock markets 11:27:22 2024-05-09 am EDT			5-day change	1st Jan Change
2.32 ^USD	-4.94%		+7.38%	+157.72%

Apr. 29	North American Morning Briefing : Investors Brace -2-	DJ
Apr. 22	North American Morning Briefing : Stock Futures -2-	DJ

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Beyondspring Announces First Patient Dosed with Pembrolizumab, Plinabulin Plus Etoposide/Platinum in A Phase 2 Investigator-Initiated Study of First-Line Extensive-Stage Small-Cell Lung Cancer	Mar. 25	CI
BeyondSpring Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	Feb. 02	CI
BeyondSpring Receives Non-Compliance Notice From Nasdaq	Jan. 10	MT
BeyondSpring Receives Notification From Nasdaq for Breaching Minimum Bid Price Requirements	Dec. 19	MT
BeyondSpring Inc. Announces New Data That Translates Preclinical Proof-Of-Concept to Clinical Evidence of Plinabulin?s Immunomodulating Activity	Nov. 07	CI
North American Morning Briefing : Focus Fixes on Fed, Powell	23-06-14	DJ
BeyondSpring Inc. Announces New Data from Phase 1 Investigator Initiated Study Plinabulin’s Ability to Reduce Infectious Neutropenic Fever for Multiple Myeloma Patients Undergoing AHCT	23-06-07	CI
BeyondSpring Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-18	CI
BeyondSpring Inc. Enrolls First Patient in Phase 2 Study with Plinabulin, Keytruda and Docetaxel in Patients with Metastatic Non-Small Cell Lung Cancer Who Progressed After Immunotherapy	23-03-01	CI
BeyondSpring Inc. Reports Earnings Results for the Half Year Ended June 30, 2022	23-02-28	CI
BeyondSpring Regains Compliance With Nasdaq's Minimum Bid Price Rule; Gets New Non-Compliance Notice for Delayed Filing	23-01-10	MT
BeyondSpring Receives Non-Compliance Notice From Nasdaq	22-11-25	MT
BeyondSpring Inc. Presents New Clinical Evidence of Plinabulin Protection of Granulocyte-Monocyte Progenitor Stem Cells for the Prevention of Chemotherapy-Induced Neutropenia at the ESMO Congress 2022	22-09-13	CI
BeyondSpring Inc. Announces Board Appointments	22-08-29	CI
BeyondSpring Presents New Data for the Use of Plinabulin and Pegfilgrastim to Decrease Neutropenia Burden in Peri-Transplant Multiple Myeloma Patients at the 19th International Myeloma Society Annual Meeting	22-08-29	CI
North American Morning Briefing : Stock Futures -2-	22-07-13	DJ
Earnings Flash (BYSI) BEYONDSPRING Posts Q4 Revenue $1.4M	22-04-14	MT
BeyondSpring Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-14	CI
BeyondSpring Pharmaceuticals Announces Organizational Streamlining	22-01-11	CI
Earnings Flash (BYSI) BEYONDSPRING Reports Q3 Revenue $337,000	21-12-30	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights BeyondSpring Inc.

Equities

BYSI

KYG108301006

Highlights

Filters